Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
  • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/60—Sugars; Derivatives thereof
  • A61K8/602—Glycosides, e.g. rutin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/52—Stabilizers

Definitions

• the present invention relates to cosmetic and dermatological preparations an effective content of boron nitride and flavone derivatives and / or flavanone derivatives, especially of flavonoids.
• the present invention relates to cosmetic Preparations with effective protection against harmful oxidation processes in the skin, but also to protect cosmetic preparations themselves or for Protection of the components of cosmetic preparations against harmful oxidation processes.
• the present invention further relates to antioxidants, preferably those which are found in skin care cosmetic or dermatological preparations are used.
• the invention also relates to cosmetic and dermatological preparations, containing such antioxidants.
• cosmetic and dermatological preparations for Prophylaxis and treatment of cosmetic or dermatological skin changes such as. skin aging, especially that caused by oxidative processes Skin aging.
• the present invention relates in particular to cosmetic and dermatological light protection formulations, prefers cosmetic and dermatological light protection formulations, which are in the form of emulsions.
• the present invention relates to active substances and preparations, such active substances containing, for cosmetic and dermatological treatment or prophylaxis erythematous, inflammatory, allergic or autoimmune-reactive symptoms, especially dermatoses.
• the harmful effect of the ultraviolet part of solar radiation on the skin is well known.
• the rays have different effects on the organ skin: the so-called UV-C radiation with a Wavelength that is less than 290 nm is from the ozone layer in the earth's atmosphere absorbed and therefore has no physiological meaning.
• the narrower range becomes the maximum of the erythema effectiveness of sunlight around 308 nm.
• UV-A radiation with a wavelength between 320 nm and 400 nm only a negligible biological Has effect and that, accordingly, the UV-B rays for most Light damage to human skin are responsible.
• UV-A radiation in terms of triggering photodynamic, especially phototoxic reactions and chronic changes the skin is far more dangerous than UV-B radiation.
• UV-B radiation can be intensified by UV-A radiation.
• UV-A rays About 90% of the ultraviolet radiation reaching the earth consists of UV-A rays. While the UV-B radiation is strong depending on numerous factors varies (e.g. time of year and day or latitude), the UV-A radiation remains independent relative to the time of year and day or geographical factors day by day constant. At the same time, the major part of UV-A radiation penetrates the living Epidermis, while about 70% of UV-B rays are retained by the horny layer become.
• the sun protection factor (SPF, often also called SPF ( s un p rotection f actor) indicates the prolongation of solar radiation, which is made possible by using the sunscreen. It is the quotient of erythema threshold time with sunscreen and erythema threshold time without sunscreen.
• the IPD method is usually used to test UV-A protection (IPD ⁇ immediate pigment darkening).
• IPD immediate pigment darkening
• - similar to the determination of the sun protection factor - Determines a value that indicates how much longer the one with the light stabilizer Protected skin can be irradiated with UV-A radiation until the same Pigmentation occurs as with unprotected skin.
• Another object of the invention was to prepare preparations in a simple and inexpensive manner to arrive, which at unusually low concentrations of conventional UV-B light protection filter substances are nevertheless acceptable or even high Achieve SPF values.
• the object of the invention was therefore also cosmetic, dermatological and pharmaceutical To create active substances and preparations as well as light protection formulations, for the prophylaxis and treatment of light-sensitive skin, especially photodermatoses, preferably serve PLD.
• Erythematous skin symptoms also appear as side effects in certain Skin disorders or irregularities. For example, the typical rash the appearance of acne regularly more or less reddened.
• Mainly antioxidants are used as protective substances against the spoilage of them containing preparations used. Nevertheless, it is known that even in human and animal skin may experience undesirable oxidation processes. Such Processes play an essential role in skin aging.
• JP-OS Hei-06-138,941 describes oral preparations with a content of water-soluble glycosides, which can be selected, for example the group ⁇ -glucosylrutin, ⁇ -glucosylmyricetin, ⁇ -glucosylisoquercitrin and ⁇ -glucosylquercitrin.
• JP-OS Hei-04-363,395 describes a process, the decomposition to prevent perfume ingredients, which can be caused by an additive on ⁇ -glucosylrutin to the corresponding preparations.
• EP-OS 586 303 and EP-OS 595 694 the use of Flavonoids as antioxidants or light protection substances in cosmetics.
• flavone derivatives flavanone derivatives or flavonoids
• flavonoids A significant disadvantage of flavone derivatives, flavanone derivatives or flavonoids is that they have some instability. Another disadvantage of these substances lies is based on the fact that they increase the products in which they are used Color concentrations yellowish, which often leads to unsightly products.
• the object of the present invention was therefore the disadvantages described to remedy the state of the art or at least to alleviate them.
• Boron nitride (BN or better B ⁇ N ⁇ ) is a homogeneous powder, which is known to improve the properties of cosmetic powder bases.
• the structures of the two main modifications of boron nitride are given schematically below, with the mesomeric boundary structures (for hexagonal ⁇ -boron nitride) and the formal charges (for cubic ⁇ -boron nitride) being omitted.
• Flavon and its derivatives are characterized by the following basic structure (substitution positions specified):
• flavones usually occur in glycosidated form.
• Flavonoids are glycosides of flavones, the flavanones, whose basic structure is characterized by the following structure: the 3-hydroxyflavones (flavonols), whose basic structure is characterized by the following structure: the Aurone, whose basic structure is characterized by the following structure: and the isoflavones, the basic structure of which is characterized by the following structure:
• the flavonoids are preferably chosen from the group of substances of the generic structural formula where Z 1 - Z 7 are selected independently of one another from the group H, OH, alkoxy and hydroxyalkoxy, where the alkoxy or hydroxyalkoxy groups can be branched and unbranched and can have 1-18 C atoms, and wherein Gly is selected from the group of mono- and oligoglycoside residues.
• the flavonoids can also be advantageously selected from the group of substances of the generic structural formula where Z 1 - Z 6 are selected independently of one another from the group H, OH, alkoxy and hydroxyalkoxy, where the alkoxy or hydroxyalkoxy groups can be branched and unbranched and can have 1-18 C atoms, and wherein Gly is selected from the group of mono- and oligoglycoside residues.
• Such structures can preferably be selected from the group of substances of the generic structural formula wherein Gly 1 , Gly 2 and Gly 3 independently of one another represent monoglycoside residues or. Gly 2 or Gly 3 can also represent, individually or together, saturations by hydrogen atoms.
• Gly 1 , Gly 2 and Gly 3 are preferably selected independently of one another from the group of the hexosyl radicals, in particular the rhamnosyl radicals and glucosyl radicals.
• hexosyl radicals for example allosyl, altrosyl, galactosyl, gulosyl, idosyl, mannosyl and talosyl, may also be used advantageously. It can also be advantageous according to the invention to use pentosyl residues.
• Z 1 - Z 5 are advantageously selected independently of one another from the group H, OH, methoxy, ethoxy and 2-hydroxyethoxy, and the flavone glycosides have the structure
• the flavone glycosides according to the invention from the group represented by the following structure are particularly advantageous; wherein Gly 1 , Gly 2 and Gly 3 independently of one another represent monoglycoside residues or. Gly 2 or Gly 3 can also represent, individually or together, saturations by hydrogen atoms.
• Gly 1 , Gly 2 and Gly 3 are preferably selected independently of one another from the group of the hexosyl radicals, in particular the rhamnosyl radicals and glucosyl radicals.
• hexosyl radicals for example allosyl, altrosyl, apiosyl, biosidyl, galactosyl, gulosyl, idosyl, mannosyl, talosyl, ascorbinyl, arabinsoyl, dulcityl, fructosyl, mannityl, rhamnosyl, ribosyl, sorbityl, xylosyl, may also advantageously be used. It can also be advantageous according to the invention to use pentosyl residues.
• the flavone glycoside or flavones is particularly advantageous to choose from the group ⁇ -glucosylrutin, ⁇ -glucosylmyrictrin, ⁇ -glucosylisoquercitriin and ⁇ -glucosylquercitrin.
• a flavonoid which is particularly advantageous according to the invention is ⁇ -glucosylrutin. It is characterized by the following structure:
• naringin aurantiin, naringenin-7-rhamnoglucoside
• hesperidin 5rd , 5,7-trihydroxy-4 -methoxyflavanon-7-rutinoside, hesperidoside, hesperetin-7-O-rutinoside. It is characterized by the following structure:
• rutin (3.3 , 4th , 5,7-pentahydroxyflavon-3-rutinoside, quercetin-3-rutinoside, sophorin, birutan, rutabion, taurutin, phytomelin, melin). It is characterized by the following structure:
• flavonoid which is particularly advantageous according to the invention is troxerutin (3,5-dihydroxy-3 ', 4', 7-tris (2-hydroxyethoxy) flavon-3- (6-O- (6-deoxy- ⁇ -L-mannopyranosyl) - ⁇ -D-glucopyranoside)). It is characterized by the following structure:
• Another flavonoid which is particularly advantageous according to the invention is monoxerutin (3.3 , 4th , 5-tetrahydroxy-7- (2-hydroxyethoxy) flavone-3- (6-O- (6-deoxy- ⁇ -L-mannopyranosyl) - ⁇ -D-glucopyranoside)). It is characterized by the following structure:
• diosmin (3 , 5,7-trihydroxy-4 methoxyflavon-7-rhamnoglucoside). It is characterized by the following structure:
• flavonoids whose glucoside residues are located in positions 3 via phenolic hydroxyl functions of the flavone , 4th and / or 5 is or are bound.
• phlorizin (1- (2- ( ⁇ -D-glucopyranosyloxy) -4,6-dihydroxyphenyl) -3- (4-hydroxyphenyl) -1-propanone), which is characterized by the following structure:
• neohesperidine dihydrochalcone (1- (4 - ((2-O- (6-deoxy- ⁇ -L-mannopyranosyl) - ⁇ -D-glucopyranosyl) oxy) -2,6-dihydroxy-phenyl) - 3- (3-hydroxy-4-methoxyphenyl) -1-propanone), which is characterized by the following structure:
• flavonoids in particular flavonoids in the strict sense, also collectively, regardless of whether a single substance or an isomer mixture or a mixture of different individual substances is present Called flavonoids "
• natural ones especially vegetable products e.g. Plant extracts in the invention Incorporate preparations that are characterized by a cosmetic or Characterize pharmaceutically acceptable flavonoids, for example according to the usual ones Process obtained aqueous, aqueous-alcoholic or aqueous-glycolic extracts as well as dry extracts.
• citrus fruit peel extract citrus fruit kernel extract
• Soybean extract e.g. the company's phytodermin commercial product Chem.Laboratorium Dr.Kurt Richter GmbH
• Sophora Japonica extract e.g. the commercial product Sophorine from Solabia
• women's thistle extract (e.g. the commercial product Psoralen Silymarin from Mani GmbH Chemical Products)
• Cat paw blossom extract spinach extract and a mixed plant extract Passion flowers, black currants and vine leaves
• calendula extract e.g. the commercial product Pot Marigold AMI watersoluble from Alban Muller
• DE-OS 44 44 238 describes combinations of cinnamic acid derivatives and flavone glycosides, for example ⁇ -glycosyl rutin as antioxidants and as Active substances against other indications.
• JP-OS Hei-06-138,941 describes oral preparations with a content of water-soluble glycosides, which can be selected, for example the group ⁇ -glucosylrutin, ⁇ -glucosylmyricetin, ⁇ -glucosylisoquercitrin and ⁇ -glucosylquercitrin.
• JP-OS Hei-04-363,395 describes a process, the decomposition to prevent perfume ingredients, which can be caused by an additive on ⁇ -glucosylrutin to the corresponding preparations.
• EP-OS 586 303 and EP-OS 595 694 the use of Flavonoids as antioxidants or light protection substances in cosmetics.
• active compound combinations according to the invention are therefore according to the invention as an antioxidant and its use in combating and / or prophylaxis skin aging caused by oxidative stress and inflammatory Reactions.
• the cosmetic or dermatological formulations according to the invention can be composed as usual and for treatment, care and cleaning serve the skin and / or hair and as a make-up product in decorative cosmetics. They preferably contain 0.01% by weight to 10% by weight, preferably 0.05% by weight to 5 % By weight, in particular 0.1-2.0% by weight, based on the total weight of the composition, on one or more flavonoids.
• cosmetic or dermatological preparations contain 0.1 to 20% by weight, advantageously 0.5 to 10% by weight, very particularly preferably 1 to 5% by weight Boron nitride.
• ⁇ -boron nitride especially those which have a has an average primary particle size of 0.1-10 ⁇ m.
• Advantageous UV-A filter substances are the phenylene-1,4-bis (2-benzimidazyl) -3,3 -5.5 -tetrasulfonic acid: and their salts, especially the corresponding sodium, potassium or triethanolammonium salts, especially the phenylene-1,4-bis (2-benzimidazyl) -3,3 -5.5 -tetrasulfonic acid bis sodium salt: as well as the 1,4-di (2-oxo-10-sulfo-3-bornylidenemethyl) benzene and its salts (especially the corresponding 10-sulfato compounds, especially the corresponding sodium, potassium or triethanolammonium salt), the is also called benzene-1,4-di (2-oxo-3-bornylidenemethyl-10-sulfonic acid) and is characterized by the following structure:
• UV-A filter substances for the purposes of the present invention are dibenzoylmethane derivatives, in particular 5-isopropyldibenzoylmethane (CAS No. 63250-25-9), which is distinguished by the structure awarded and sold by Merck under the brand Eusolex® 8020, and / or the 4- (tert-butyl) -4 -methoxydibenzoylmethane (CAS No. 70356-09-1), which is characterized by the structure awarded and sold by Givaudan under the Parsol® 1789 brand.
• dibenzoylmethane derivatives in particular 5-isopropyldibenzoylmethane (CAS No. 63250-25-9), which is distinguished by the structure awarded and sold by Merck under the brand Eusolex® 8020, and / or the 4- (tert-butyl) -4 -methoxydibenzoylmethane (CAS No. 70356-09-1), which is characterized by the structure awarded and sold by Givaudan under
• Further light protection filter substances to be used advantageously in the sense of the present invention have the structural element of the methylidene camphor, for example the 4-methylbenzylidene camphor, which is distinguished by the structure distinguished and sold by Merck under the Eusolex® 6300 brand, as well as the benzylidene camphor, which is characterized by its structure awarded and sold by the company Induchem under the brand name Unisol® S22.
• the structural element of the methylidene camphor for example the 4-methylbenzylidene camphor, which is distinguished by the structure distinguished and sold by Merck under the Eusolex® 6300 brand, as well as the benzylidene camphor, which is characterized by its structure awarded and sold by the company Induchem under the brand name Unisol® S22.
• the substances which contain the structural motif of benzophenone can be advantageous (in this document also as Benzophenones "designated) are selected from the group of the following substances also benzophenone-11, CAS no. 1341-54-4.
• benzophenone is benzophenone-3, which is available, for example, from Merck the product name Eusolex® 4360 is sold.
• Further light protection filter substances which are advantageous in the sense of the present invention are cinnamic acid esters, for example 2-ethylhexyl p-methoxycinnamate (4-methoxycinnamic acid-2 ethylhexyl ester), which is available from Givaudan under the name Parsol® MCX and is characterized by the following structure:
• UV filter substances in the sense of the present invention are also so-called Broadband filter, i.e. Filter substances that contain both UV-A and UV-B radiation absorb.
• Examples of advantageous broadband filters are bis-resorcinyltriazine derivatives with the following structure: where R 1 , R 2 and R 3 are independently selected from the group of branched and unbranched alkyl groups having 1 to 10 carbon atoms or a single hydrogen atom.
• R 1 , R 2 and R 3 are independently selected from the group of branched and unbranched alkyl groups having 1 to 10 carbon atoms or a single hydrogen atom.
• UV filter is the 4,4 ', 4''(1,3,5-triazine-2,4,6-triyltriimino) tris-benzoic acid tris (2-ethylhexyl ester), synonymous: 2, 4,6-tris- [anilino- (p-carbo-2'-ethyl-1'-hexyloxy)] - 1,3,5-triazine.
• This UV-B filter substance is marketed by BASF Aktiengesellschaft under the brand name UVINUL® T 150 is marketed and is characterized by good UV absorption properties out.
• the main disadvantage of 4,4 ', 4' '- (1,3,5-triazine-2,4,6-triyltriimino) tris-benzoic acid tris (2-ethylhexyl ester) is its poor solubility in lipids. It prepared therefore in the past certain difficulties in formulation, with the help this filter to achieve higher sun protection factors, but what the teaching of the invention could be overcome.
• UV filter substances whose incorporation into cosmetic or dermatological light protection formulations has problems are also known.
• European Offenlegungsschrift 775 698 describes bis-resorcinyltriazine derivatives whose chemical structure is represented by the generic formula is reproduced, wherein R 1 , R 2 and A 1 represent a wide variety of organic radicals.
• UV filter is the 2.2 -Methylene-bis- (6- (2H-benzotnazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol), which is characterized by the chemical structural formula is marked.
• UV filters mentioned used in the sense of the present invention of course, should not be limiting.
• the total amount of oil-soluble UV filter substances in the finished cosmetic or dermatological preparations for example 4,4 ', 4''- (1,3,5-triazine-2,4,6-triyltriimino) -tris-benzoic acid tris ( 2-ethylhexyl ester) and / or 4- (tert-butyl) -4 methoxydibenzoylmethane and / or 4-methylbenzylidene camphor is advantageously selected from the range from 0.1 to 10.0% by weight, based on the total weight of the preparations, if the presence of these substances is desired.
• the total amount of 2-ethylhexyl p-methoxy cinnamate in the finished cosmetic or dermatological preparations if the presence of this substance is desired is advantageous from the range of 0.1-15.0% by weight, preferably 0.5-7.5 % By weight, based on the total weight of the preparations.
• the total amount of ethylhexyl-2-cyano-3,3-diphenyl acrylate in the finished cosmetic or dermatological preparations if the presence of this substance is desirable, advantageously in the range of 0.1-15.0% by weight, preferably 0.5-10.0 % By weight, based on the total weight of the preparations.
• the total amount of one or more salicylic acid derivatives in the finished cosmetic or dermatological preparations is advantageous from the range of 0.1-15.0% by weight, preferably 0.5-8.0% by weight, based on the total weight of the preparations. If ethylhexyl salicylate is chosen, it is of advantage Total amount in the range from 0.1 to 5.0% by weight, preferably 0.5 to 2.5% by weight to choose. If homomenthyl salicylate is chosen, it is beneficial to its total amount from the range of 0.1-10.0% by weight, preferably 0.5-5.0% by weight choose.
• Cosmetic and dermatological formulations in the sense of the invention contain one or several conventional UV-A, UV-B and / or broadband filters as individual substances or in any mixtures with one another, in the lipid phase and / or in the aqueous Phase.
• the total amount of UV filter substances (UV-A, UV-B and / or broadband filter) in the finished cosmetic or dermatological preparations is advantageous from the range of 0.1 to 30% by weight, preferably 0.1 to 20.0% by weight, in particular 0.5 to 15.0% by weight selected, based on the total weight of the preparations.
• Cosmetic and dermatological preparations according to the invention also advantageously, although not necessarily, contain inorganic pigments based on metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular the oxides of titanium (TiO 2 ), zinc (ZnO), iron (for example Fe 2 O 3 ), zirconium (ZrO 2 ), silicon (SiO 2 ), manganese (e.g. MnO), aluminum (Al 2 O 3 ), cerium (e.g. Ce 2 O 3 ), mixed oxides of the corresponding metals and mixtures of such oxides.
• These pigments are X-ray amorphous or non-X-ray amorphous. It is particularly preferred to use pigments based on TiO 2 .
• X-ray amorphous oxide pigments are metal oxides or semimetal oxides, which contribute to X-ray diffraction experiments reveal no or no discernible crystal structure to let. Such pigments are often obtainable by flame reaction, for example in that a metal or semimetal halide with hydrogen and air (or pure Oxygen) is implemented in a flame.
• X-ray amorphous oxide pigments as thickening and thixotropic agents, flow aids, for emulsion and dispersion stabilization and as a carrier (for example used to increase the volume of finely divided powders or powders).
• X-ray amorphous oxide pigments are the silicon oxides of the type Aerosil® (CAS No. 7631-86-9. Aerosile®, available from DEGUSSA, are characterized by low Particle size (e.g. between 5 and 40 nm), the particles being spherical particles very uniform dimensions can be seen. Aerosile® are macroscopic as loose, white powder recognizable. For the purposes of the present invention, X-ray amorphous Silicon dioxide pigments are particularly advantageous, and just these are among them of the Aerosil® type preferred.
• Aerosil® types are, for example, Aerosil® OX50, Aerosil® 130, Aerosil® 150, Aerosil® 200, Aerosil® 300, Aerosil® 380, Aerosil® MOX 80, Aerosil® MOX 170, Aerosil® COK 84, Aerosil® R 202, Aerosil® R 805, Aerosil® R 812, Aerosil® R 972, Aerosil® R 974, Aerosil® R976.
• cosmetic or dermatological light protection preparations 0.1 to 20% by weight, advantageously 0.5 to 10% by weight, very particularly preferably 1 to 5 % By weight of X-ray amorphous oxide pigments.
• the non-X-ray amorphous inorganic pigments are advantageous according to the invention in a hydrophobic form, i.e. that they are treated to be water-repellent on the surface.
• This surface treatment can consist in that the pigments are known per se Process can be provided with a thin hydrophobic layer.
• n and m are stoichiometric parameters to be used at will, R and R 'are the desired organic radicals.
• R and R ' are advantageous.
• Advantageous TiO 2 pigments are available, for example, under the trade name T 805, advantageous TiO 2 / Fe 2 O 3 mixed oxides under the trade name T 817 from Degussa.
• the total amount of inorganic pigments, especially hydrophobic inorganic Micropigments in the finished cosmetic or dermatological preparations is advantageously in the range of 0.1-30% by weight, preferably 0.1-10.0, in particular 0.5 - 6.0% by weight, based on the total weight of the preparations.
• the cosmetic and / or dermatological formulations according to the invention can be composed as usual and the cosmetic and / or dermatological Sun protection, also for the treatment, care and cleaning of the skin and / or the hair and as a make-up product in decorative cosmetics.
• the preparations according to the invention can, for example can be used as skin protection cream, cleansing milk, sun protection lotion, Nutrient cream, day or night cream, etc. It may be possible and advantageous, the preparations according to the invention as a basis for pharmaceutical Use wording.
• the cosmetic and dermatological agents according to the invention are used Preparations in the usual way for cosmetics on the skin and / or the hair sufficient amount applied.
• Such cosmetic and dermatological preparations are particularly preferred, which are in the form of a sunscreen. These can also be advantageous at least to UV-A, UV-B and / or broadband filters used according to the invention contain an inorganic pigment, preferably an inorganic micropigment.
• the cosmetic and dermatological preparations according to the invention can Contain cosmetic auxiliaries, as they are usually used in such preparations e.g. Preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments that have a coloring effect, thickeners, moisturizing and / or moisturizing substances, fats, oils, waxes or other usual components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
• cosmetic auxiliaries e.g. Preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments that have a coloring effect, thickeners, moisturizing and / or moisturizing substances, fats, oils, waxes or other usual components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
• the amounts of cosmetic or dermatological auxiliary and Carriers and perfume can vary depending on the type of product can be easily determined by a specialist simply by trying it out.
• antioxidants are generally preferred. According to the invention can be used as cheap antioxidants all for cosmetic and / or dermatological Suitable or customary antioxidants are used.
• the antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. ⁇ -carotene, ⁇ -carotene, lycopene) and their derivatives, chlorogenic acid and their derivatives, lipoic acid and their derivatives (e.g.
• amino acids eg glycine, histidine, tyrosine, tryptophan
• imidazoles eg urocanic acid
• peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (e.g. anserine)
• carotenoids e.g
• thiols e.g. thioredoxin, Glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholesteryl and glyceryl esters
• salts dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
• buthioninsulfoximines homocysteine sulfoximine, buthioninsulfones, penta-, hexa-, H eptathioninsulfoxmin
• very low tolerable doses e.g. pmol to ⁇ mol / kg
• metal chelators e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin
• ⁇ -hydroxy acids e.g. citric acid, lactic acid, malic acid
• humic acid bile acid , Biliary extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g.
• ⁇ -linolenic acid linoleic acid, oleic acid
• folic acid and their derivatives ubiquinone and ubiquinol and their derivatives
• vitamin C and derivatives e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate
• tocopherols and derivatives e.g.
• vitamin E acetate
• vitamin A and derivatives vitamin A palmitate
• stilbenes and their derivatives e.g. stilbene oxide, trans-stilbene oxide
• derivatives suitable according to the invention salts, esters, ethers, sugars, nucleotides, Nucleosides, peptides and lipids
• the amount of the aforementioned antioxidants (one or more compounds) in the Preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05% 20% by weight, in particular 0.1-5% by weight, based on the total weight of the preparation.
• vitamin E and / or its derivatives are the antioxidant (s) advantageous, the respective concentrations of which range from 0.001-10% by weight, based on the total weight of the formulation.
• vitamin A or vitamin A derivatives or carotenes or their derivatives are advantageous, their respective concentrations from the Range of 0.001-10% by weight based on the total weight of the formulation choose.
• the ester is advantageously chosen from the group from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length from 3 to 30 carbon atoms.
• ester oils can then advantageously be chosen from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2-octyldodecyl palmitate, Oleyl oleate, Oleylerucat, Erucyloleat, Erucylerucat as well as synthetic, semi-synthetic and natural mixtures of such esters, e.g. Jojoba oil.
• the oil phase can advantageously be selected from the group of the branched ones and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, as well as the fatty acid triglycerides, namely the saturated triglycerol esters and / or unsaturated, branched and / or unbranched alkane carboxylic acids Chain length from 8 to 24, in particular 12 - 18 carbon atoms.
• the fatty acid triglycerides can advantageously be selected from the group of synthetic, semi-synthetic and natural oils, e.g. Olive oil, sunflower oil, soybean oil, peanut oil, Rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like.
• any mixtures of such oil and wax components are also advantageous To use the sense of the present invention. It can also be advantageous if necessary be waxes, for example cetyl palmitate, as the sole lipid component of the oil phase to use.
• the oil phase is advantageously selected from the group consisting of 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 12-15 alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.
• hydrocarbons paraffin oil, squalane and squalene are advantageous in the sense of the present invention.
• the oil phase can also advantageously contain cyclic or linear silicone oils have or consist entirely of such oils, although preferred will, in addition to the silicone oil or the silicone oils, an additional content of others To use oil phase components.
• Cyclomethicone (octamethylcyclotetrasiloxane) is advantageous as according to the invention using silicone oil. But other silicone oils are also beneficial in the sense to use the present invention, for example hexamethylcyclotrisiloxane, Polydimethylsiloxane, poly (methylphenylsiloxane).
• Mixtures of cyclomethicone and isotridecyl isononanoate are also particularly advantageous. from cyclomethicone and 2-ethylhexyl isostearate.
• Glycerol monostearate SE 4.50 Ceteareth-20 1.00 Dicaprylyl ether 5.00 Cetearyl isononanoate 5.00 Dimethicone 2.00 Boron nitride 1.00 Conservation 0.50 Glycerin 5.00 Na citrate 0.50 ⁇ -glucosylrutin 0.50 water ad 100.00

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Chemical & Material Sciences (AREA)
• Inorganic Chemistry (AREA)
• Cosmetics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=7909030

Family Applications (1)

Country Status (2)

Cited By (1)

Families Citing this family (1)

Citations (4)

Family Cites Families (4)

• 1999
  • 1999-05-22 DE DE1999123772 patent/DE19923772A1/de not_active Withdrawn
• 2000
  • 2000-05-05 EP EP00109132A patent/EP1055415A3/fr not_active Ceased

Patent Citations (4)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events